We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Proposed changes to the statutory scheme to control the costs of branded health service medicines.
An agreement between DHSC and the ABPI on getting the best value and most effective medicines into use more quickly.
Sets out the payment due from members of the voluntary scheme for branded medicines pricing and access in 2021.
The outline terms agreed between DHSC and the Association of the British Pharmaceutical Industry (ABPI) for the voluntary scheme.
Minutes of meetings held between government, NHS England and the ABPI to review the operation of the 2019 voluntary scheme for branded medicines pricing and access.
Provides information on how the Pharmaceutical Price Regulation Scheme (PPRS) is controlling spend on branded medicines in the NHS.
Examines factors influencing the 5.19% growth in branded medicines under the Pharmaceutical Price Regulation Scheme (PPRS) in 2013 to 2014.
An agreement between DHSC, NHS England and ABPI to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector.
Sets out the payment due from members of the voluntary scheme for branded medicines pricing and access in 2023.
Sets out the payment due from members of the voluntary scheme for branded medicines pricing and access in 2020.
Sets out the payment due from members of the voluntary scheme for branded medicines pricing and access in 2022.
Information on how the voluntary scheme for branded medicines pricing and access is controlling spend on branded medicines in the NHS.
This guidance provides information on comparator products used in studies supporting abridged marketing authorisation applications
The key terms of the agreement reached between the Department of Health and Social Care, NHS England and the Association of the British Pharmaceutical Industry for a new voluntary scheme.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).